Resource Center
The Past, Present and Future of TA-TMA Targeted Therapies
Join us for an insightful discussion with Dr. Anthony Sabulski, a renowned expert in TA-TMA among HSCT patients. Dr. Sabulski's vital research has focused on identifying at-risk patients and implementing early interventions to enhance transplant outcomes. In this webinar, explore the latest treatment strategies aimed at improving post-transplant patient lives, including a comprehensive review of past and present approaches to TA-TMA, the efficacy of C5 inhibition, and emerging therapies shaping future directions in TA-TMA management. Don't miss this opportunity to delve into cutting-edge insights and optimize treatment outcomes. Includes a Q&A Session.
Featured Resource
Immunity Testing: CMV in Lung Transplant Patients
This bi-lateral lung transplant recipient is a 65 year-old male patient who received his lung transplant due to end-stage lung disease secondary to non-CF bronchiectasis. The donor and recipient CMV serostatus is D+/R+. The patient’s initial peri-operative course was complicated by difficult explant, primary graft dysfunction, respiratory failure requiring prolonged mechanical ventilation, renal insufficiency and recurrent infectious concerns, including pseudomonas and stenotrophomonas pneumonias.
Search the Eurofins Viracor online test directory
for the most up-to-date assay offerings and information
Test Menu